Nasdaq's determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable initial listing standards for The Nasdaq ...

Phased Rollout The platform will initially feature Full Alliance Group–owned or licensed products, including popular wellness lines Feromos and Jusspray HOCl. Future phases will open the network to ...

This U.S.-based manufacturing agreement builds upon Oragenics’ broader strategy to develop scalable, accessible, and fast-acting treatments for neurological trauma, beginning with concussion, a ...

NeuroRush™ delivers a unique blend of adaptogens and nootropic herbs designed to enhance cognitive performance, stress response and long-term brain health, without dependency or burnout.

Two remaining SPC-15 studies are currently in progress or being planned: an IND-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetic animal study, and a device study of ...

The CardiAMP HF cell therapy trials are important for patients with ischemic heart failure in need of new therapies,” said Gerald Koenig, MD, Director of the Cardiac Catheterization Laboratory, Henry ...

Plug and Play will provide a dedicated team to support every phase of the process – from actively scouting startups aligned with Chiesi’s needs to promoting the initiative through its Open Innovation ...

Lattimore’s move to Air represents a major milestone in its broader technology modernization strategy. By consolidating billing, charting, and ambient documentation into a single, AI-enabled system, ...

LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has received a letter from the Nasdaq Hearings Panel ...

The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the launch of its enhanced Virtual Trip video conference platform featuring the first selection of videos from Psychedelic ...

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and ...

The successful recent installation and validation of this iHP isolator is the first completed deployment of the SIS-SA, part of the SteraMist Integrated Systems (SIS) launched in the second half of ...